1Retrospective screening for SARS-CoV-2 among 5,800 hospitalizations related to influenza-like2illness during the 2018-19 pre-pandemic and 2019-2020 pandemic influenza seasons in the

3 VAHNSI network, Spain.

- 4
- 5 Ainara Mira-Iglesias^{1*}, Beatriz Mengual-Chuliá^{1*}, Laura Cano¹, Javier García-Rubio¹,
- 6 Miguel Tortajada-Girbés³, Mario Carballido-Fernández^{4,5}, Juan Mollar-Maseres⁶,
- 7 Germán Schwarz-Chavarri⁷, Sandra García-Esteban¹, Joan Puig-Barberà, Javier Díez-Domingo^{1&},
- 8 F. Xavier López-Labrador^{1,2,&,#}, for the Valencia Hospital Network for the Study of Influenza and
- 9 Respiratory Viruses Disease¹

10

- 1. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat
- 12 Valenciana (FISABIO-Public Health), Valencia, Spain

13 2. Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto

- 14 de Salud Carlos III, Madrid, Spain
- 15 3. Hospital Doctor Peset, Valencia, Spain
- 16 4. Hospital General Universitario de Castellón, Castellón, Spain
- 17 5. Universidad CEU Cardenal Herrera, Castellón, Spain
- 18 6. Hospital Universitario y Politécnico La Fe, Valencia, Spain
- 19 7. Hospital General de Alicante, Alicante, Spain.
- 20 (*) Contributed equally, both authors act as first authors.
- 21 (&) Both authors act as senior authors.
- 22 (##) Members of the VAHNSI network listed at the end of the manuscript.
- 23 # Corresponding author: F. Xavier López-Labrador. F.Xavier.Lopez@uv.es
- 24 Corresponding author mailing address: Virology Laboratory, Genomics & Health Area,
- 25 FISABIO-Public Health. Avenida de Cataluña, 21. 46020 Valencia, Spain.
- 26
- 27
- 28
- ---
- 29
- 30
- 31
- 32

33 Abstract

34 On March 9 2020 the WHO Global Influenza Program (GIP) asked participant sites on the Global 35 Influenza Hospital Surveillance Network (GIHSN) to contribute to data collection concerning 36 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We re-analysed 5,833 viral RNA 37 archived samples collected prospectively from hospital admissions for influenza-like illness (ILI) in the Valencia Region of Spain by the VAHNSI network (4 hospitals, catchment area population 38 39 1,118,732) during the prepandemic 2018/2019 (n=4,010) and pandemic 2019/2020 (n=1,823) 40 influenza seasons, for the presence of SARS-CoV-2. We did not find evidence for community-41 acquired SARS-CoV-2 infection in hospital admissions for ILI in our region before early March 42 2020.

43

44 Introduction

45 The first case of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome 46 coronavirus (SARS-CoV-2) was detected in Wuhan (Hubei province, China) at the end of 2019 47 and the virus rapidly spread to other Chinese provinces and countries (1). As of 3 June 2020, the 48 World Health Organization (WHO) had already reported the presence of SARS-CoV-2 in 54 49 different European countries (2). In Spain, the first imported and locally acquired COVID-19 cases 50 were detected on 31 January, and 26 February 2020, respectively (3, 4). Since then, until 51 beginning of June, Spain accounted for 240,660 confirmed cases and 27,133 deaths. Among total 52 registered deaths, 86% were in people aged 70 or older and 95% had previous underlying chronic 53 conditions (5). Symptomatology described by SARS-CoV-2-infected patients was almost identical 54 to the common influenza-like illness (ILI) symptoms (6, 7), and COVID-19 cases may have 55 occurred in Spain earlier than previously recognized (8). Besides, there is no data available on 56 potential SARS-CoV-2 circulation during the prepandemic 2018/2019 influenza season.

57

58 Methods

59 Every influenza season, from November to March/April, the Valencia Hospital Surveillance 60 Network for the Study of Influenza and Other Respiratory Viruses (VAHNSI) network conducts a 61 prospective active-surveillance study on respiratory viral infections in 4 hospitals, providing healthcare to 1,118,732 (22% of total) inhabitants from the Valencia Region of Spain (Figure 1). 62 63 Our network is integrated in the Global Influenza Hospital Surveillance Network (GIHSN) sharing data with the WHO GIP (www.gihsn.org/). Full-time dedicated nurses screen all hospitalized 64 patients discharged from the Emergency Department if they referred a complain possibly 65 related to a respiratory infection. Patients are included in the study if they are resident in the 66 67 catchment area of one of the participating hospitals, non-institutionalised and not discharged 68 from a previous admission in the last 30 days. Patients have to meet the ECDC influenza-like 69 illness (ILI) case definition (9), defined as the presence of, at least, one systemic symptom (fever 70 or feverishness, malaise, myalgia or headache) and, at least, one respiratory symptom 71 (shortness of breath, sore throat or cough), with an onset of symptoms in the 7 days prior to 72 admission. For children less than 5 years old, we only require an onset of one symptom (Table 73 S1) in the 7 days prior to admission. Finally, patients need to be in hospital between 8 and 48 74 hours to be enrolled and swabbed (combined nasopharyngeal and oropharyngeal in universal 75 transport medium), after written informed consent. Clinical and demographic characteristics 76 from patients were obtained by a face-to-face interview or by consulting medical records.

77

78 Samples are tested in one centralized laboratory (FISABIO-Public Health) by real-time reverse-79 transcription polymerase chain reaction (RT-PCR) for 19 different viruses (influenza 80 A(H1N1)pdm09, A(H3N2), B/Victoria and B/Yamagata, Respiratory Syncytial Virus (RSV) A and B, 81 metapneumovirus, parainfluenza 1-4, rhinovirus/enterovirus, adenovirus, bocavirus, and 82 coronavirus 229E, HKU1, NL63 and OC43). First, all available samples from the 2019/2020 season 83 were re-analysed individually to detect SARS-CoV-2. An in-house assay was rapidly developed in 84 February 2020 based in the WHO-Charité and U.S. CDC assays, to detect the SARS-CoV-2 E-gene 85 (10) in multiplex together with the human cellular control RNAse-P to ensure reliability of sample 86 collection and nucleic acid extraction before RT-PCR. Only samples with RNAse-P Ct values <35 87 were considered valid. The limit of detection of the assay was established to 35 copies using the 88 SARS-CoV-2 E-gene as reference material either as an insert in a pCDNA plasmid (a gift from Luis 89 Enjuanes, Coronavirus laboratory, CNB-CSIC, Madrid, Spain) or as encapsulated RNA (a gift from 90 Charité Medical Center, Berlin, though the European Virus Archive program). Further, to 91 investigate the possibility of SARS-CoV-2 infection earlier to fall-winter 2019 than previously 92 recognized, we retrospectively tested in pools of 10 samples available archived viral RNAs from 93 nasopharyngeal samples collected from 4,010 individuals admitted because of ILI during the 94 2018/2019 influenza season. The Ethics Research Committee of the Dirección General de Salud 95 Pública-Centro Superior de Investigación en Salud Pública (DGSP-CSISP) previously approved the 96 protocol for the study of respiratory viruses in the VANSHI network.

97

98 Results

A total of 5,176 patients were recruited in the VAHNSI network between November 2019 and
 mid-March, 2020 and 1,843 were included after applying exclusion criteria; 1,291 of them were
 PCR-negative for the 19 tested seasonal viruses and the remainder 552 had at least one
 detectable virus. After re-testing 1,823 available samples for SARS-CoV-2, either positive or

103 negative for seasonal viruses, only one SARS-CoV-2 positive was detected. The result was 104 replicated in an independent sample at the hospital laboratory. Whole-genome sequencing was 105 performed by metagenomic sequencing with spiked primer enrichment, MSSPE (11), using a primer set described by Manning et al. (https://www.protocols.io/view/sars-cov-2-enrichment-106 107 sequencing-by-spiked-primer-bc36iyre), and showed three amino acid changes from the hCoV-108 19/Wuhan/WIV04/2019 strain (P323L in NSP12, L117M in NSP8, and D614G in the S protein), 109 belonging to GISAID G clade and PANGOLIN B.1.5 lineage. The infected patient was a man in his 110 late 70's who was admitted to hospital on early March 2020 (epidemiological week 11/2020) for 111 acute respiratory infection with fever, cough and malaise, with symptom onset 2 days prior to 112 admission. Co-morbidities included diabetes and a prostate adenocarcinoma, but not obesity or 113 smoking history. During hospitalization, he was not admitted in the Intensive Care Unit (ICU) nor 114 required mechanical ventilation or extracorporeal membrane oxygenation (ECMO). However, 115 the patient died five days after admission. As main discharge diagnosis, the ICD10-CM code J06.9 116 was registered (acute upper respiratory tract infection, unspecified). Finally, all RNA pools from 117 the 4,010 archived samples belonging to the prepandemic 2018/19 influenza season (back to 118 September 2018) were SARS-CoV-2 RT-PCR negative.

119

120 Discussion

121 To our knowledge, our study is the first comprehensive screening for SARS-CoV-2 in ILI cases at 122 the population level in the prepandemic period in Europe. We describe here the first SARS-123 CoV-2 admission in the Valencia Region without travel history and thus likely due to 124 community transmission in early March, 2020. The infected patient was an old diabetic man in 125 his late 70's who was also developing a neoplasia. It is widely known that COVID19 mainly 126 affects elderly people (12, 13) as well as people with underlying chronic conditions (14) 127 including diabetes in an important percentage of severe cases (15, 16). Our patient had a weak 128 health status. Apart from his chronic conditions, he had other frailty indicators (data available 129 upon request). Although the patient was not admitted in the ICU, he finally died 5 days after 130 admission.

131

The first COVID19 cases in Spain were imported cases detected on 31 January 2020 in a German tourist in La Gomera, Canary Islands and in continental Spain on February 26, in an Italian returning from Milan (3, 4). In the Valencia Region of Spain, the first identified case was also imported (travel history to Nepal in late December 2019), detected in early February 2020 in a Hospital not covered by our surveillance network (17). Excess cases of influenza detected by analysis of primary care electronic medical records suggested an earlier circulation of SARS- CoV-2 in other regions of Spain (8), but no laboratory identification of SARS-CoV-2 was
attempted. Retrospective identification of SARS-CoV-2 was also recently suggested in swabs
collected for other diagnoses or in hospitalised cases with pneumonia in Spain, so the
epidemic may had gone unnoticed prior to first case of local transmission (18). Unfortunately,
laboratory data on that observation are yet unpublished.

143

144 Countries from the Northern Hemisphere were already engaged in seasonal influenza control 145 when the SARS-CoV-2 outbreak started in China. Therefore, influenza surveillance systems 146 with wide screening windows are perfect tools to retrospectively analyse the presence of the 147 new SARS-CoV-2, because COVID19 shares most of the ILI symptomatology such as fever and 148 cough (12). The first study based in retrospective analysis of samples from ILI cases was 149 performed in Wuhan, China (October 2019-January 2020), detecting the first SARS-CoV-2 cases in the first week of January 2020, concomitant with significantly higher ILI cases for the 2019-150 151 2020 winter in comparison to previous years (19). In contrast, in our network of 4 tertiary-care 152 hospitals in South-eastern Spain (covering a population of more than 1 million), the time of the 153 first non-travel related SARS-CoV-2 hospital admission we detect is early March 2020 and 154 coincided with the end of the peak of influenza and other respiratory viruses (Fig. 2). In 155 addition, ILI inpatient cases for the 2019–2020 winter were not significantly higher in 156 comparison to previous years: average percentage inpatients with ILI were 30% in 2019-20 in 157 our catchment area, as compared to 36% during 2018-19, with no increased ILI cases during 158 the first 10 epidemiological weeks. Phylodynamic analyses estimated the origin of SARS-CoV-2 159 clusters in Spain around mid-February 2020 (21), which probably later completely replaced 160 circulating seasonal respiratory viruses quickly in our region (Figure 2). In line with our results, 161 SARS-CoV-2 was not detected in similar retrospective studies on inpatients limited to few cases 162 in another region of Spain (n=170; 1 January - 25 February 2020) (20), central Italy (n=166; 1 163 November 2019 - 1 March 2020) (22), or in only 2/2,888 inpatients and outpatients who had 164 negative results by routine respiratory virus testing in the United States between 1 January 165 2020 - 26 February 2020 (23). Collectively, our results and published data indicate that the 166 early pandemic phase was still dominated by seasonal respiratory viruses, with very low 167 circulation of SARS-CoV-2 in the community and probably a limited period of overlap with 168 influenza circulation (24-25). Whether pre-existing immune memory and innate immune 169 interference shaped SARS-CoV-2 spread deserves further investigation (24).

170

The first SARS-CoV-2 cases in hospital admissions in Europe had been identified at the end ofJanuary or early February 2020 as related to travel to, or to contacts with, travellers from China

173 (26-28). Later, retrospective analysis identified earlier cases from early or late December 2019 174 in Italy and France, respectively (29, 30). Some studies have suggested circulation of SARS-CoV-175 2 may have occurred even earlier than December 2019. A retrospective study on blood samples 176 from Italy found SARS-CoV-2 receptor-binding domain (RBD) specific antibodies as early as 177 September 2019 (30) but whether this observation is due to cross-reactivity with common cold 178 coronaviruses or true SARS-CoV-2 infection is unknown. Previous retrospective sample studies 179 based on RT-PCR testing are limited to 2020 or late December 2019 (22-24, 29, 30). In contrast, 180 we analyzed ILI samples back to September 2018, and found no evidence supporting SARS-CoV-181 2 circulation in hospitalized community-acquired ILI during the prepandemic 2018/2019 or 182 pandemic 2019/2020 influenza seasons, prior to early March 2020.

183

184 Our study has several limitations. First, the VAHNSI network was designed for detecting 185 influenza cases, therefore COVID19 cases presenting a symptomatology different from 186 influenza were not detected. Second, the pandemic disruption situation forced the 187 interruption of hospital surveillance activities in mid-March, just after the declaration of the 188 state of alarm by the Spanish Government. More cases of SARS-CoV-2 would have been 189 detected should the study had not been stopped. Finally, it is possible that pooled testing for 190 2018-19 samples led to lower RT-PCR sensitivity. However, pool sizes of up to 10 samples have 191 been proven to maintain high performance when compared with individual sample testing (23, 192 32).

193

194 Despite these limitations, here we show how influenza surveillance networks are a powerful 195 resource to analyse the presence of the new respiratory viruses sharing the ILI / SARI 196 symptomatology, because routine collection and storage of samples months (and eventually 197 years) before the occurrence of a new virus introduction. Using these networks will allow us to 198 expand surveillance of SARS-CoV-2, to detect unexpected pathogens in the future, and to 199 elaborate a better map and seasonality for SARS-CoV-2 circulation during the next influenza 200 season. The transition of influenza surveillance networks to other respiratory viruses is thus 201 warranted.

202

203 Acknowledgements.

FXLL and BMC is supported by the CIBEResp, Instituto de Salud Carlos III, Spain. Data collection
was partially supported by a grant from the Foundation for Influenza Epidemiology (FIE), which
supports the Global Influenza Hospital Surveillance Network (see www.gihsn.org for more
details). The sponsor did not participate in the study design, data analysis and interpretation,

- in the writing of the manuscript or in the decision to submit the manuscript for publishing. The
- 209 authors thank the staff of Hospital General de Castellón, in Castellón; Hospital La Fe, in
- 210 Valencia; Hospital Doctor Peset, in Valencia; Hospital General de Alicante, in Alicante for their
- support and contribution to the Valencia Hospital Network for the Study of Influenza and
- 212 Respiratory Viruses Disease (VAHNSI) network.
- 213

214 References

- 1. WHO. Novel Coronavirus (2019-nCoV). Situation report 1. 21 January 2020: World Healh
- 216 Organization; 2020 [Available from: https://www.who.int/docs/default-
- source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4.
- 218 2. WHO. Coronavirus disease (COVID-19) Situation Report-135: World Healh Organization;
- 219 2020 [Available from: https://www.who.int/docs/default-source/coronaviruse/situation-
- 220 reports/20200603-covid-19-sitrep-135.pdf?sfvrsn=39972feb_2.
- 3. Centro Nacional de Epidemiología, Instituto de Salud Carlos III (ISCIII). Primeros casos
- investigados en España por Covid-2019. Informe Covid-2019 no 1. [First Covid-19 cases in
- 223 Spain. Covid-2019 report no 1]. Madrid: ISCIII; 2020. Spanish. Available from:
- 224 https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTra
- 225 nsmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-
- 226 19.%20N%c2%ba%201_11febrero2020_ISCIII.pdf
- 4. Instituto de Salud Carlos III (ISCIII). Informe sobre los casos de COVID-19 confirmados en
- 228 España Informe COVID-19 no 3. [Report on confirmed COVID-19 cases in Spain. COVID-19
- 229 report no 3]. Madrid: ISCIII; 2020. Spanish. Available from:
- 230 https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTra
- 231 nsmisibles/Documents/INFORMES/Informes%20COVID-19/Informe%20COVID-
- 232 19.%20N%c2%ba%203_28febrero2020_ISCIII.pdf
- 233 5. Ministerio de Sanidad. Actualización nº 126. Enfermedad por el coronavirus (COVID-19)
- 234 04.06.2020: Ministerio de Sanidad. Gobierno de España.; 2020 [Available from:
- 235 https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-
- 236 China/documentos/Actualizacion_126_COVID-19.pdf.
- 237 6. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
- 238 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
- 239 7. Wang L, He WB, Yu XM, Hur DL, Bao MW, Liu HF, et al. Coronavirus disease 2019 in elderly
- 240 patients: Characteristics and prognostic factors based on 4-week follow-up. Journal of
- 241 Infection. 2020;80(6):639-45.
- 242 8. Coma E, Mora N, Prats-Uribe A, Fina F, Prieto-Alhambra D, Medina-Peralta M. Excess cases
- of influenza suggest an earlier start to the coronavirus epidemic in Spain than official figures
- tell us: an analysis of primary care electronic medical records from over 6 million people from

- 245 Catalonia. medRxiv 2020:2020.2004.2009.20056259. Available from:
- 246 http://dx.doi.org/2020.04.09.20056259
- 247 9. European Commission. Commission Implementing Decision of 8 August 2012 amending
- 248 Decision 2002/253/EC laying down case definitions for reporting communicable diseases to the
- 249 Community network under Decision No. 2119/98/EC of the European Parliament and of the
- 250 Council (notified under document C(2012) 5538). European Commission. Luxembourg:
- 251 Publications Office of the European Union; 2012 [Available from: https://eur-
- 252 lex.europa.eu/legal-
- content/EN/TXT/PDF/?uri=CELEX:32012D0506&qid=1428573336660&from=EN#page=16.
- 254 10. WHO. Molecular assays to diagnose COVID-19: Summary table of available protocols. 24
- 255 January 2020. https://www.who.int/publications/m/item/molecular-assays-to-diagnose-covid-
- 256 19-summary-table-of-available-protocols
- 257 11. Deng X, Achari A, Federman S, Yu G, Somasekar S, Bártolo I, et al. Metagenomic sequencing
- with spiked primer enrichment for viral diagnostics and genomic surveillance. Nat Microbiol.
 2020 Mar;5(3):443-454.
- 260 12. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus
- 261 Disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-20.
- 13. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison
 with young and middle-aged patients. Journal of Infection. 2020;80(6):E14-E8.
- 264 14. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid Chronic Diseases are Strongly Correlated with
- Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis. Aging and
 Disease. 2020;11(3):668-78.
- 15. Wu J, Zhang J, Sun X, Wang L, Xu Y, Zhang Y, et al. Influence of diabetes mellitus on the
 severity and fatality of SARS-CoV-2 infection. Diabetes, obesity & metabolism. 2020.
- 269 16. Shi M, Chen L, Yang Y, Zhang J, Xu J, Xu G, et al. Analysis of clinical features and outcomes
- of 161 patients with severe and critical COVID-19: A multicenter descriptive study. Journal of
- clinical laboratory analysis. 2020:e23415.
- 272 17. Navarro Conde P, Alemany Monraval P, Medina Medina C, Jiménez Sánchez A, Andrés
- 273 Teruel JC, Ferrando Marco J, et al. Autopsy findings from the first known death from Severe
- 274 Acute Respiratory Syndrome SARS-CoV-2 in Spain. Revista Española de Patología
- 275 2020;53(3):188-192.

- 18. Working group for the surveillance and control of COVID-19 in Spain. The first wave of the
- 277 COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as
- 278 at 27 April 2020. Eurosurveillance, 25, 2001431 (2020), https://doi.org/10.2807/1560-

279 7917.ES.2020.25.50.2001431

- 280 19. Kong W-H, Li Y, Peng M-W, Kong D-G, Yang X-B, Wang L, et al. SARS-CoV-2 detection in
- patients with influenza-like illness. Nature Microbiology 2020;5(5):675-678.
- 282 https://doi.org/10.1038/s41564-020-0713-1
- 20. Diez-Fuertes F, Iglesias-Caballero M, García-Pérez J, Monzón S, Jiménez P, Varona S, et al. A
 Founder Effect Led Early SARS-CoV-2 Transmission in Spain. Journal of Virology
 2021;95(3):e01583-01520.
- 286 21. Blanco-Suarez A, Pérez-Jové P, Escribano-Castillejo N, Ballestero-Tellez M. Retrospective
- 287 search of SARS-CoV-2 in respiratory samples in Vallès Occidental (Barcelona, Spain) before the

first case was reported. Enfermedades Infecciosas y Microbiología Clínica 2020;38(10):511-


- 289 512.
- 290 22. Capalbo C, Bertamino E, Zerbetto A, Santino I, Petrucca A, Mancini R, et al. No Evidence of
- 291 SARS-CoV-2 Circulation in Rome (Italy) during the Pre-Pandemic Period: Results of a
- 292 Retrospective Surveillance. International Journal of Environmental Research and Public Health293 2020;17(22).
- 23. Hogan C, Garamani N, Sahoo M, Huang C, Zehnder J, Pinsky B. Retrospective Screening for
- 295 SARS-CoV-2 RNA in California, USA, Late 2019. Emerging Infectious Disease journal
- 296 2020;26(10):2487.PMID: 32620178 PMCID: PMC7510744 DOI: 10.3201/eid2610.202296
- 297 24. Leuzinger K, Roloff T, Gosert R, Sogaard K, Naegele K, Rentsch K, et al. Epidemiology of
- 298 Severe Acute Respiratory Syndrome Coronavirus 2 Emergence Amidst Community-Acquired
- 299 Respiratory Viruses. The Journal of Infectious Diseases 2020 1/8/2021;222(8):1270-1279.
- 300 25. Stowe J, Tessier E, Zhao H, Guy R, Muller-Pebody B, Zambon M, et al. Interactions between
- 301 SARS-CoV-2 and Influenza and the impact of coinfection on disease severity: A test negative
- 302 design. MedRxiv 2020:2020.09.18.20189647. https://doi.org/10.1101/2020.09.18.20189647.
- 26. Olsen SJ, Meng-Yu C, Yu-Lun L, Mark W, Alexis A, Clementine C, et al. Early Introduction of
 Severe Acute Respiratory Syndrome Coronavirus 2 into Europe. Emerging Infectious Disease
 journal 2020;26(7).

- 306 27. Lescure F-X, Bouadma L, Nguyen D, Parisey M, Wicky P-H, Behillil S, et al. Clinical and
- virological data of the first cases of COVID-19 in Europe: a case series. The Lancet Infectious
 Diseases 2020;20(6):697-706.
- 309 28. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of
- coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February
 2020. 2020;25(9):2000178.
- 312 29. Amendola A, Bianchi S, Gori M, Colzani D, Canuti M, Borghi E, et al. Evidence of SARS-CoV-2
- RNA in an Oropharyngeal Swab Specimen, Milan, Italy, Early December 2019. Emerging
 Infectious Disease journal 2020;27(2).
- 30. Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar JR, et al. SARS-
- CoV-2 was already spreading in France in late December 2019. International Journal of
- 317 Antimicrobial Agents 2020;55(6):106006.
- 318 31. Apolone G, Montomoli E, Manenti A, Boeri M, Sabia F, Hyseni I, et al. Unexpected
- detection of SARS-CoV-2 antibodies in the prepandemic period in Italy. Tumori Journal 2020
- 320 2020/11/17:0300891620974755.
- 321 32. Hogan CA, Sahoo MK, Pinsky BA. Sample Pooling as a Strategy to Detect Community
- 322 Transmission of SARS-CoV-2. JAMA; 2020. p. 1967-1969.PMID: 32250394 PMCID:
- 323 PMC7136853 DOI: 10.1001/jama.2020.5445.



Figure 1. Map of the covered population area in south-east Spain (red). The number of

- inhabitants covered by the VAHNSI network is 1,118,732.



330

Figure 2. Number of detections for 19 respiratory viruses in the VAHNSI network during the

- 332 2019/20 influenza season by epidemiological week (November 1st 2019 to March 14th 2020).
- 333 The timing for the first ILI admission positive for SARS-CoV-2 is indicated.

334